Stock DMTK DERMTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages DermTech, Inc.

Equities

DMTK

US24984K1051

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
0.629 USD -0.06% Intraday chart for DermTech, Inc. +4.29% -64.06%
04-22 North American Morning Briefing : Stock Futures -2- DJ
04-19 Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63 MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types
DermTech, Inc. Simplifies the DermTech Melanoma Test by Discontinuing the Optional TERT Add-On Assay
Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test
DermTech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
DermTech Signs Contract With Highmark For Enhanced Access to DermTech Melanoma Test
DermTech Inc Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test
Dermtech Appoints Mark Aguillard as Chief Commercial Officer
DermTech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023
DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay
DermTech Signs Agreement With Hawaii Blues Plan to Enhance Melanoma Test Access
DermTech, Inc. Announces Contract with Hawaii Blues Plan for the Foundational Assay of Its Dermtech Melanoma Test
DermTech, Inc. Announces Agreements with South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test
DermTech, Inc. Announces Management Changes
DermTech, Inc. Announces Change of CEO
DermTech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMTK Stock
  4. News DermTech, Inc.
  5. Other languages